These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10578605)

  • 1. [Primary HIV-1 infection].
    Meyer L; Goujard C
    Rev Prat; 1999 Oct; 49(16):1750-5. PubMed ID: 10578605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
    Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.
    Barbour JD; Hecht FM; Little SJ; Markowitz M; Daar ES; Kelleher AD; Routy JP; Campbell TB; Rosenberg ES; Segal MR; Weidler J; Grant RM
    AIDS; 2006 Oct; 20(16):2123-5. PubMed ID: 17053362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
    Delaugerre C; Marcelin AG; Soulié C; Chaix ML; Katlama C; Girard PM; Calvez V; Morand-Joubert L
    AIDS; 2007 Jun; 21(10):1365-7. PubMed ID: 17545716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies.
    Oxenius A; Price DA; Trkola A; Edwards C; Gostick E; Zhang HT; Easterbrook PJ; Tun T; Johnson A; Waters A; Holmes EC; Phillips RE
    J Infect Dis; 2004 Aug; 190(4):713-21. PubMed ID: 15272399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J
    AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary HIV type 1 infection.
    Kassutto S; Rosenberg ES
    Clin Infect Dis; 2004 May; 38(10):1447-53. PubMed ID: 15156484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary HIV infection and the acute retroviral syndrome.
    Rosenberg E; Cotton D
    AIDS Clin Care; 1997 Mar; 9(3):19, 23-5. PubMed ID: 11364121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and virological markers in HIV infection.
    Vella S
    AIDS Clin Care; 1995 May; 7(5):37-40. PubMed ID: 11362683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New knowledge and new challenges: 4th National Conference on Retroviruses & Opportunistic Infections].
    Agosto M; Ehara R
    Sidahora; 1997; ():18-21. PubMed ID: 11364490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?
    Goujard C; Chaix ML; Lambotte O; Deveau C; Sinet M; Guergnon J; Courgnaud V; Rouzioux C; Delfraissy JF; Venet A; Meyer L;
    Clin Infect Dis; 2009 Sep; 49(6):982-6. PubMed ID: 19681706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response.
    Zanchetta M; Anselmi A; Vendrame D; Rampon O; Giaquinto C; Mazza A; Accapezzato D; Barnaba V; De Rossi A
    Antivir Ther; 2008; 13(1):47-55. PubMed ID: 18389898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.